Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 103502. Отображено 100.
12-01-2012 дата публикации

Use of Molecular Chaperones for the Enhanced Production of Secreted, Recombinant Proteins in Mammalian Cells

Номер: US20120009670A1
Автор: Hsinyi Yvette Tang, Ruth Kelly, Sham-Yuen Chan, Yiwen Tao, Yongjian Wu
Принадлежит: Bayer Pharmaceuticals Corp

The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.

Подробнее
Номер записи: 1
12-01-2012 дата публикации

Recombinant surfactant protein d compositions and methods of use thereof

Номер: US20120010126A1
Автор: Howard Clark, Kenneth Bannerman Milne Reid, Palaniyar Nadesalingam, Peter Strong
Принадлежит: Medical Research Council

We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

Подробнее
Номер записи: 2
12-01-2012 дата публикации

Lactoferrin compositions and methods of wound treatment

Номер: US20120010150A1
Автор: Atul Varadhachary, Jose Engelmayer
Принадлежит: Agennix Inc

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Подробнее
Номер записи: 3
12-01-2012 дата публикации

Composition comprising various proteorhodopsins and/or bacteriorhodopsins and use thereof

Номер: US20120010333A1
Автор: Bradley R. Kelemen, Gregory M. Whited, II Donald E. Ward, Rasmus B. Jensen, Richard R. Bott
Принадлежит: DANISCO US INC, Genencor International Inc

The present invention provides a solid material comprising an immobilized mixture of two or more proteorhodopsins, two or more bacteriorhodopsins, or one or more bacteriorhodopsin and one or more proteorhodopsins. The proteorhodopsins are selected from the group consisting of all-trans-retinal-containing proteorhodopsins and retinal analog-containing proteorhodopsins; all of which have absorption spectra that do not overlap. The bacteriorhodopsins are selected from the group consisting of all-trans-retinal-containing bacteriorhodopsins and retinal analog-containing bacteriorhodopsins; all of which have absorption spectra that do not overlap. The present invention also provides an optical information carrier, such as an optical data storage material and a fraud-proof optical data carrier, comprising the above-described solid material and a substrate selected from the group consisting of glass, paper, metal, fabric material, and plastic material, wherein said solid material is deposited on said substrate. The present invention further provides security ink comprising one or more hydrophilic polymers and a mixture of various photochromic materials.

Подробнее
Номер записи: 4
19-01-2012 дата публикации

Complement receptor 2 targeted complement modulators

Номер: US20120015871A1
Автор: Stephen Tomlinson, V. Michael Holers
Принадлежит: MUSC Foundation for Research Development, University of Colorado

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Подробнее
Номер записи: 5
19-01-2012 дата публикации

Estrogen receptors and methods of use

Номер: US20120016109A1
Автор: Zhao Yi Wang
Принадлежит: CREIGHTON UNIVERSITY

The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.

Подробнее
Номер записи: 6
26-01-2012 дата публикации

Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins

Номер: US20120021484A1
Автор: Kevin A. McDonnell
Принадлежит: BIOGEN IDEC MA INC

The invention is directed to methods of purifying Fc-containing molecules using a soluble neonatal Fc receptor (sFcRn). Native FcRn binds Fc-containing proteins at or below about pH 6.5 and releases them at or above about pH 7 and provides a much milder approach for capturing and purifying Fc-containing proteins, in particular, therapeutic Fc-containing proteins. Other embodiments of the invention provide modifications to alter the pH for binding and elution to the sFcRn, to modulate Fc-containing protein binding affinity, to affect sFcRn linkage to a support surface, or to improve the stability of sFcRn to conditions utilized in the methods of the invention.

Подробнее
Номер записи: 7
02-02-2012 дата публикации

Thermoreversible collagen

Номер: US20120027732A1
Автор: Sherry L. Voytik-Harbin
Принадлежит: PURDUE RESEARCH FOUNDATION

This invention relates to collagen formulations. More particularly, this invention relates to thermoreversible collagen formulations and methods of their use and preparation.

Подробнее
Номер записи: 8
02-02-2012 дата публикации

Apj receptor compounds

Номер: US20120028888A1
Автор: Athan Kuliopulos, Jay Janz, Thomas J. Mcmurry
Принадлежит: ANCHOR THERAPEUTICS Inc

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

Подробнее
Номер записи: 9
09-02-2012 дата публикации

Cell lines producing blocking antibodies to human RANKL

Номер: US20120034690A1
Автор: Dirk M. Anderson
Принадлежит: Immunex Corp

Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.

Подробнее
Номер записи: 10
16-02-2012 дата публикации

Collagen peptide composition having good ability to enter the blood and food or beverage containing the same

Номер: US20120040055A1
Автор: Hidetoshi Nishizawa, Hiroki Ohara, Hitoshi Matsumoto, Koichi Terauchi, Masataka Hata
Принадлежит: Meiji Co Ltd

An object of the present invention is to elucidate a collagen peptide effective for causing dipeptides or tripeptides serving as the active component to enter the blood, and thus to reduce the required intake thereof. According to the present invention, a collagen peptide composition obtained by digesting collagen or gelatin with protease is provided, wherein: (a) the ratio of hydroxyproline to total of amino acid residues at the second position from the N terminus of the peptides in the composition is 2 mol % or more and 20 mol % or less, and the ratio of glycine to total of amino acid residues at the third position from the N terminus of the peptides in the composition is 20 mol % or more and 50 mol % or less; and (b) the average molecular weight is 500 or more and 2000 or less.

Подробнее
Номер записи: 11
16-02-2012 дата публикации

Novel collagen materials and methods for obtaining same

Номер: US20120040119A1
Автор: Christian Gagnieu, Patricia Forest, Sylvain Picot
Принадлежит: BiomUp France SAS

The invention relates to novel collagen materials and, specifically, collagen membranes, tubes and threads. Said materials combine enhanced properties of resilience and strength. The invention also relates to a method for preparing collagen materials using acid fibrous collagen comprising coagulation and, optionally, cross-linking of the collagen in the presence of ammonia gas.

Подробнее
Номер записи: 12
16-02-2012 дата публикации

Identification of novel antagonist toxins of t-type calcium channel for analgesic purposes

Номер: US20120040909A1
Автор: Emmanuel Bourinet, Fabrice Marger, Joël Nargeot, Michel Lazdunski, Pierre Escoubas
Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Universite de Nice Sophia Antipolis UNSA

A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one.

Подробнее
Номер записи: 13
01-03-2012 дата публикации

Immunogenic epitopes of ngep antigen

Номер: US20120052116A1
Автор: Ira Pastan, Jeffrey Schlom, Kwong-Yok Tsang
Принадлежит: US Department of Health and Human Services

The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.

Подробнее
Номер записи: 14
01-03-2012 дата публикации

Methods of diagnosing cervical cancer

Номер: US20120052484A1
Автор: Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer, Michael P. Belmares, Peter S. Lu
Принадлежит: Individual

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

Подробнее
Номер записи: 15
01-03-2012 дата публикации

Method for temporally controlling the biological activity of proteins in vertebrates, and applications thereof

Номер: US20120052570A1
Автор: Daniel Metzger, Huimin Zhao, John Katzenellenbogen, Pierre Chambon
Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Universite De Strasbourg, University of Illinois

The present invention relates to a method for tightly temporally controlling the biological activity of a protein of interest in a vertebrate, upon induction of the activity of a fusion protein comprising said protein of interest and an ERM polypeptide containing a mutated ligand binding domain of the human oestrogen receptor α, with a synthetic ligand that does not interfere with oestrogen signalling. In particular, the present invention concerns a method for generating tightly temporally-controlled targeted somatic mutations in a vertebrate, preferably a mouse, by inducing the activity of a fusion protein comprising a site-specific recombinase protein and an ERM polypeptide, with a synthetic ligand devoid of oestrogenic and anti-oestrogenic activities.

Подробнее
Номер записи: 16
08-03-2012 дата публикации

method for promoting bone growth using activin-actriia antagonists

Номер: US20120058115A1
Автор: Jasbir Seehra, John Knopf
Принадлежит: Acceleron Pharma Inc

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.

Подробнее
Номер записи: 17
08-03-2012 дата публикации

Neuroprotective iron chelators and pharmaceutical compositions comprising them

Номер: US20120058945A1
Автор: Abraham Warshawsky, Hailin Zheng, Matitiyahu Fridkin, Moussa Youdim, Rivka Warshawsky
Принадлежит: Technion Research and Development Foundation Ltd, Yeda Research and Development Co Ltd

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.

Подробнее
Номер записи: 18
08-03-2012 дата публикации

Methods and compositions for modification of a hla locus

Номер: US20120060230A1
Автор: Andreas Reik, Edward J. Rebar, Fyodor Urnov, Jeffrey C. Miller, Laurence J.N. Cooper, Michael C. Holmes, Philip D. Gregory, Trevor Collingwood
Принадлежит: Individual

Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

Подробнее
Номер записи: 19
15-03-2012 дата публикации

Psca: prostate stem cell antigen and uses thereof

Номер: US20120063999A1
Автор: Aya Jakobovitz, Douglas C. Saffran, Owen N. Witte, Robert E. Reiter
Принадлежит: Agensys Inc, UNIVERSITY OF CALIFORNIA

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Подробнее
Номер записи: 20
15-03-2012 дата публикации

Il-17 homologous polypeptides and therapeutic uses thereof

Номер: US20120064073A1
Автор: Audrey Goddard, Austin L. Gurney, Colin K. Watanabe, Daniel G. Yansura, Daniel Tumas, Dorothy French, Ellen Fllvaroff, Hanzhong Li, J. Christopher Grimaldi, James Pan, Jian Chen, Kenneth J. Hillan, Melissa A. Starovasnik, Menno Van Lookeren, P. Mickey Williams, Paul J. Godowski, Richard Vandlen, Sarah G. Hymowitz, Sherman Fong, William I. Wood
Принадлежит: Individual

The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Подробнее
Номер записи: 21
15-03-2012 дата публикации

Therapeutic use of anti-cs1 antibodies

Номер: US20120064083A1
Автор: Gao Liu, J. Yun Tso, Marna Williams, Nicholas F. Landolfi
Принадлежит: Abbott Biotherapeutics Corp

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Подробнее
Номер записи: 22
15-03-2012 дата публикации

Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface

Номер: US20120065136A1
Автор: Hironao Wakabayashi, Philip J. Fay
Принадлежит: UNIVERSITY OF ROCHESTER

The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.

Подробнее
Номер записи: 23
15-03-2012 дата публикации

Methods of processing recombinant procollagen

Номер: US20120065376A1
Автор: Amit Yaari, Hanan Stein, Michal Rosenthal, Oded Shoseyov, Or Dgany, Tamar Haya Tal
Принадлежит: Collplant Ltd

A method of generating atelocollagen is disclosed. The method comprises contacting a human telopeptide-comprising collagen with a protease selected from the group consisting of neutrase, subtilisin, ficin recombinant human trypsin and recombinant human pepsin, wherein said human telopeptide-comprising collagen is expressed in a non-animal cell, thereby generating the atelocollagen. Compositions comprising the atelocollagen generated thereby are also disclosed.

Подробнее
Номер записи: 24
22-03-2012 дата публикации

Methods of treating inflammation

Номер: US20120070449A1
Автор: Einat Toister, Idit Shachar
Принадлежит: Yeda Research and Development Co Ltd

A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation.

Подробнее
Номер записи: 25
22-03-2012 дата публикации

Targeted multi-epitope dosage forms for induction of an immune response to antigens

Номер: US20120070493A1
Автор: Christopher Fraser, David H. Altreuter, Grayson B. Lipford
Принадлежит: Selecta Biosciences Inc

Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.

Подробнее
Номер записи: 26
22-03-2012 дата публикации

Compositions and methods for identifying enzyme and transport protein inhibitors

Номер: US20120071344A1
Автор: Roland Wolkowicz
Принадлежит: SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION

The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.

Подробнее
Номер записи: 27
22-03-2012 дата публикации

Therapeutic application of isolated naturally-occuring soluble truncated forms of IL-23 receptor

Номер: US20120071422A1
Автор: Grant Gallagher, Jonathan Brazaitis, Raymond Yu
Принадлежит: Medical Diagnostic Laboratories LLC

The present invention relates to an isolated naturally-occurring soluble truncated IL-23Rα protein, which is a translated protein resulting from a mRNA splice variant of IL-23Rα. The soluble IL-23Rα proteins (e.g., Δ9 and Δ8,9) represents a novel soluble IL-23Rα protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that Δ9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23Rα protein. More importantly, the present invention provides an utility application of the Δ9 and Δ8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, Δ9 and Δ8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of Δ9 and Δ8,9 in treating a human patient inflicted with Crohn's disease.

Подробнее
Номер записи: 28
29-03-2012 дата публикации

Materials and Methods for the Treatment of Pathological Neovascularization in the Eye

Номер: US20120077870A1
Автор: C. Kathleen DOREY, Howard M. Prentice, Janet C. BLANKS
Принадлежит: Blanks Janet C, Dorey C Kathleen, Prentice Howard M

The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD.

Подробнее
Номер записи: 29
05-04-2012 дата публикации

Soluble il-17ra/rc fusion proteins and related methods

Номер: US20120082668A1
Автор: Gao Zeren, Mark W. Rixon, Steven D. Levin
Принадлежит: Zymogenetics Inc

Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Подробнее
Номер записи: 30
05-04-2012 дата публикации

Botulinum Neurotoxin B Receptors and Use Thereof

Номер: US20120082672A1
Автор: Edwin Raymond Chapman, Min Dong
Принадлежит: Individual

It is disclosed here that synaptotagmin I (syt I) and synaptotagmin II (syt II) are the cellular receptors for botulinum neurotoxin B (BoNT/B) that mediate the cellular entry and toxicity of BoNT/B. The BoNT/B binding domains of syt I and II are also disclosed. While syt I needs gangliosides for BoNT/B binding, syt II can bind to BoNT/B in the absence of gangliosides. Various nucleic acids and polypeptides that relate to the BoNT/B binding domain of syt I or II are disclosed. Further disclosed are methods of reducing BoNT/B toxicity, methods of identifying agents that can block the binding between BoNT/B and syt I or II, methods of identifying agents that can bind to the BoNT/B binding domain of syt I or II, methods of detecting BoNT/B or Clostridium botulinum and kits for use thereof.

Подробнее
Номер записи: 31
05-04-2012 дата публикации

Human cytokine receptor

Номер: US20120082673A1
Автор: Scott R. Presnell, Steven D. Hughes, Wayne R. Kindsvogel, Wenfeng Xu, Zhi Chen
Принадлежит: Zymogenetics Inc

Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”

Подробнее
Номер записи: 32
05-04-2012 дата публикации

Compositions Containing HC-HA Complex and Methods of Use Thereof

Номер: US20120083445A1
Автор: Hua He, Scheffer Tseng
Принадлежит: TissueTech Inc

Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof

Подробнее
Номер записи: 33
12-04-2012 дата публикации

Therapeutics for age-related macular degeneration

Номер: US20120087928A1
Автор: Kameran Lashkari
Принадлежит: Individual

The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.

Подробнее
Номер записи: 34
12-04-2012 дата публикации

Immunocompromised Ungulates

Номер: US20120090039A1
Автор: Amy DANDRO, David L. Ayares, Kevin Wells, Michael Mendicino
Принадлежит: Individual

Porcine animals, tissue and organs as well as cells and cell lines derived from such animals are provided that lack functional endogenous immunoglobulin loci and are deficient in immunoglobulin expression and B-cells. These animals are useful as model systems for research and for development of new pharmaceutical and biological agents. In addition, methods are provided to prepare such animals.

Подробнее
Номер записи: 35
19-04-2012 дата публикации

Peptide fragments for inducing synthesis of extracellular matrix proteins

Номер: US20120093740A1
Автор: Lijuan Zhang, Scott M. Harris, Timothy J. Falla
Принадлежит: Helix Biomedix Inc

Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.

Подробнее
Номер записи: 36
26-04-2012 дата публикации

CD86 Antagonist Multi-Target Binding Proteins

Номер: US20120100139A1
Автор: John W. Blankenship, Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, Sateesh Kumar Natarajan
Принадлежит: Emergent Product Development Seattle LLC

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Подробнее
Номер записи: 37
10-05-2012 дата публикации

Collagen extraction from aquatic animals

Номер: US20120114570A1
Автор: Awis Qurni Sazili, Badlishah Sham Baharin, Dzulkifly Mat Hashim, Harvinder Kaur, Jamilah Bakar, Kaur Harvinder, Russly Abdul Rahman, Umi Hartina Mohamad Razali
Принадлежит: UNIVERSITI PUTRA MALAYSIA (UPM)

The present invention relates to the use of fish skin as novel industrial source of collagen. Advantageously, said skin is obtained after the filleting or cutting of the fresh fish and frozen immediately after filleting/cutting, thus guaranteeing a very good quality of the base material, both from the bacteriological standpoint and from the standpoint of the native property of the protein.

Подробнее
Номер записи: 38
10-05-2012 дата публикации

Tslp promotes immune evasion and persistence of viruses

Номер: US20120114596A1
Автор: Bernhard Homey, Isabel Fernandez, Vassili Soumelis
Принадлежит: HEINRICH-HEINE-UNIVERSITAET, INSTITUT CURIE, Institut National de la Sante et de la Recherche Medicale INSERM

It relates to the treatment or prevention of a chronic viral infection with a Thymic Stromal Lymphopoietin (TSLP) antagonist thereby avoiding immune evasion and persistence of the virus. It also provides a method of prognosing the evolution of a cervical dysplasia by TSLP expression in a sample of said cervical dysplasia.

Подробнее
Номер записи: 39
10-05-2012 дата публикации

Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn- ligands engage a novel receptor ifn-rn (crf2-12) and il-10r2 (crf2-4) for signaling andinduction of biological activities

Номер: US20120114603A1
Автор: Grant F. Gallagher, Sergei Kotenko
Принадлежит: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

Подробнее
Номер записи: 40
10-05-2012 дата публикации

Compositions comprising angiogenic factors and methods of use thereof

Номер: US20120114685A1
Автор: Catherine Sewell, Duane Sewell, Matthew Seavey, Paulo Maciag, Yvonne Paterson
Принадлежит: University of Pennsylvania Penn

The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.

Подробнее
Номер записи: 41
10-05-2012 дата публикации

Integrin heterodimer and an alpha subunit thereof

Номер: US20120114708A1
Автор: Donald Gullberg
Принадлежит: HANSA MEDICAL AB

A recombinant or isolated integrin heterodimer comprising a novel subunit α11 in association with a subunit β is described. The integrin or the subunit α11 can be used as marker or target of all types of cells. The integrin or subunit α11 thereof can be used as marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.

Подробнее
Номер записи: 42
17-05-2012 дата публикации

Antibodies that immunospecifically bind to b lymphocyte stimulator protein

Номер: US20120121606A1
Автор: David Hilbert, Gil H. Choi, Steven C. Barash, Steven M. Ruben, Tristan Vaughan
Принадлежит: Human Genome Sciences Inc

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Подробнее
Номер записи: 43
17-05-2012 дата публикации

Anti-estrogen and immune modulator combinations for treating breast cancer

Номер: US20120121620A1
Автор: David A. Sirbasku
Принадлежит: Individual

Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to treatment with a composition containing an immune inhibitor or an immune inhibitor mimicking compound are also disclosed. Preferred methods include identifying in a specimen of cancer cells the presence of a Poly-Ig (Fe) receptor or Poly-Ig-like (Fc) receptor capable of binding to an immune inhibitor or an immune inhibitor mimicking compound and of mediating immune inhibition of cancer cell growth.

Подробнее
Номер записи: 44
17-05-2012 дата публикации

Peptide

Номер: US20120121625A1
Автор: David Wraith
Принадлежит: Apitope Technology Bristol Ltd

The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.

Подробнее
Номер записи: 45
17-05-2012 дата публикации

cRGD PEPTIDE DERIVATIVE AND ITS MANUFACTURE, AND IMPLANT HAVING A COATING CONTAINING A cRGD PEPTIDE DERIVATIVE

Номер: US20120121682A1
Автор: Alexander Borck
Принадлежит: BIOTRONIK AG

Various embodiments of the invention relate to a cRGD peptide derivative and an associated manufacturing method, and to an implant having a coating containing a cRGD peptide derivative. One aspect of the invention is the provision of a cRGD peptide derivative having the formula (1): wherein x=0-8, in particular 4-8, and R is a hydrophobic group.

Подробнее
Номер записи: 46
17-05-2012 дата публикации

Autoantibody production inhibitor

Номер: US20120123099A1
Автор: Masayuki Homma
Принадлежит: Nihon Pharmaceutical Co Ltd

The present invention provides an autoantibody production inhibitor which can specifically suppress the autoantibodies and which can effectively prevent or treat the autoimmune disease of autoantibody type. According to the present invention, there is provided an autoantibody production inhibitor comprising, as an effective ingredient, a fusion protein which consists of a protein (X) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type and a protein (A) containing a fragment which exhibits the antibody-dependent cellular cytotoxicity of the antibody heavy chain constant region.

Подробнее
Номер записи: 47
24-05-2012 дата публикации

Truncated cd20 protein, deltacd20

Номер: US20120129167A1
Автор: Carole Henry, Christophe Borg, Christophe Ferrand, Marina Deschamps, Pierre Tiberghien, Pierre-Simon Rohrlich
Принадлежит: Francais du Sang Ets

The present invention relates in particular to a protein from an alternative splicing of the gene encoding CD20, the nucleic acid sequences encoding the protein according to the invention, a mutated form of the CD20 gene as well as drugs, diagnostic tools, diagnostic methods and treatment methods using the protein and the nucleic acid sequences according to the invention.

Подробнее
Номер записи: 48
24-05-2012 дата публикации

Inhibition of ApoE Cleavage Activity in the Treatment of ApoE-Related Disorders

Номер: US20120129782A1
Автор: Karl H. Weisgraber, Mei Xiu Steele, QIN Xu, Robert W. Mahley, Stephen Barry Freedman, Yadong Huang
Принадлежит: J David Gladstone Institutes

The present invention provides methods for treating apoE-related disorders. The methods generally involve administering an effective amount of an agent that inhibits activity of an enzyme that cleaves apoE.

Подробнее
Номер записи: 49
31-05-2012 дата публикации

Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination

Номер: US20120134993A1
Автор: Carl W. Birks, Pallavur V. Sivakumar, Qi Pan
Принадлежит: Zymogenetics Inc

Disclosed are bispecific binding proteins comprising a antibody/soluble receptor bispecific binding protein that reduces the biological activity of both VEGF-A and FGF. The FGF binding moieties are generally soluble FGFR3 or FGFR2. An Fc polypeptide is fused to the C-terminus of the FGF binding moiety and VEGF-A binding moiety are polypeptides fused using peptide or polypeptide linker sequences, and can be expressed as single bispecific binding protein. The bispecific antibody/soluble receptor binding proteins can be used to treat cancers characterized by solid tumor growth as well as other diseases.

Подробнее
Номер записи: 50
31-05-2012 дата публикации

Crystal of Human Glycoprotein VI Collagen Binding Domain

Номер: US20120135880A1
Автор: Andrew B. Herr, Katsunori Horii
Принадлежит: Individual

A crystal comprising the collagen binding domain of human GPVI is provided and defined by structural atomic coordinates. Employing computer modeling based on the crystal structure, including methods for identifying inhibitors of GPVI collagen binding activity, methods for screening libraries of compounds for potential to bind to the GPVI collagen binding domain, and methods of identifying a compound useful for the treatment of a GPVI-mediated disorder, are also provided.

Подробнее
Номер записи: 51
07-06-2012 дата публикации

Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System

Номер: US20120141456A1
Автор: Kenneth J. Rhodes, R. Blake Pepinsky, Sha Mi
Принадлежит: BIOGEN IDEC MA INC

The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

Подробнее
Номер записи: 52
07-06-2012 дата публикации

Molecular complexes which modify immune responses

Номер: US20120141482A1
Автор: Abdel Hamad, Jonathan Schneck, Michael S. Lebowitz, Sean O'herrin
Принадлежит: JOHNS HOPKINS UNIVERSITY

Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.

Подробнее
Номер записи: 53
07-06-2012 дата публикации

Methods for treating inflammation using b7-h4 polypeptides and fragments thereof

Номер: US20120141504A1
Автор: Lieping Chen
Принадлежит: Mayo Foundation for Medical Education and Research

The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.

Подробнее
Номер записи: 54
07-06-2012 дата публикации

Methods and compositions for prognosing and detecting age-related macular degeneration

Номер: US20120141994A1
Автор: Margaret M. DeAngelis, Margaux Morrison
Принадлежит: MASSACHUSETTS EYE AND EAR INFIRMARY

The invention provides methods and compositions for determining whether a subject is at risk of developing age-related macular degeneration, for example, the wet or neovascular form of age-related macular degeneration. The method involves determining whether the subject has a protective variant and/or a risk variant at a polymorphic site in the RORA gene. A protective or risk variant may be defined by a haplotype in the RORA gene.

Подробнее
Номер записи: 55
14-06-2012 дата публикации

Polypeptide formulation

Номер: US20120148587A1
Автор: Richard L. Remmele, Jr., Wayne R. Gombotz
Принадлежит: Immunex Corp

The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.

Подробнее
Номер записи: 56
14-06-2012 дата публикации

Trp inhibitors and uses thereof

Номер: US20120148604A1
Автор: Eric M. Ostertag, John Stuart Crawford
Принадлежит: Transposagen Biopharmaceuticals Inc

The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.

Подробнее
Номер записи: 57
21-06-2012 дата публикации

Targeting agent to newly formed blood vessels

Номер: US20120156132A1
Автор: Kentaro Nakamura, Yasuhiko Tabata
Принадлежит: Fujifilm Corp, KYOTO UNIVERSITY

It is an object of the present invention to provide a targeting agent that enables drug delivery to a neovascular site and the imaging of such a neovascular site, utilizing the effect of the agent to accumulate in the neovascular site. The present invention provides a targeting agent to a neovascular site, which comprises a gelatin-like protein.

Подробнее
Номер записи: 58
21-06-2012 дата публикации

Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases

Номер: US20120156214A1
Автор: Fabienne MacKay, Jeffrey L. Browning, Paul D. Rennert, Paula S. Hochman
Принадлежит: BIOGEN IDEC MA INC

Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Подробнее
Номер записи: 59
21-06-2012 дата публикации

Microorganism for expressing a human membrane protein

Номер: US20120156695A1
Автор: Andreas Raab, Christine Lang, Michael Schilling
Принадлежит: ORGANOBALANCE GMBH

The invention relates to an isolated, genetically modified, living non-mammal organism, having increased HMG-CoA-reductase activity compared to the wild type, and having reduced C24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type. The invention further relates to different uses of such an organism, to a test kit comprising such an organism, and to a membrane extract of such an organism.

Подробнее
Номер записи: 60
12-07-2012 дата публикации

Human cdr-grafted antibody and antibody fragment thereof

Номер: US20120177643A1
Автор: Akiko Shimizu, Emi Hosaka, Kazuyasu Nakamura, Kenya Shitara, Masamichi Koike
Принадлежит: Kyowa Hakko Kirin Co Ltd

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Подробнее
Номер записи: 61
12-07-2012 дата публикации

Fusion proteins comprising cd4 minimal modules and methods of use thereof

Номер: US20120177657A1
Автор: Barbara Capecchi, Indresh K. Srivastava, Maria Scarselli, Rino Rappuoli, Susan W. Barnett, Vega Masignani, Victoria Sharma
Принадлежит: Novartis Vaccines and Diagnostics Inc

Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.

Подробнее
Номер записи: 62
12-07-2012 дата публикации

Compositions and methods for treatment of cervical dysplasia

Номер: US20120177678A1
Автор: John Rothman, Yvonne Paterson
Принадлежит: Individual

The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and an E7 and/or E6 antigen. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.

Подробнее
Номер записи: 63
12-07-2012 дата публикации

Screening of protein candidates

Номер: US20120178110A1
Автор: Jianbing Zhang, Tomoko Hirama
Принадлежит: NATIONAL RESEARCH COUNCIL OF CANADA

Successful application of an engineered protein as therapeutics or in other industries would require the protein to have good expression level, good biophysical properties and often desired affinity to its target. The present invention provides a method of screening large numbers of protein candidates (PCs) in all three aspects simultaneously. PCs are fused to a protein anchor, which is captured by the target/antigen. The captured PCs are evaluated for their expression levels, biophysical properties and affinities using conventional methods.

Подробнее
Номер записи: 64
12-07-2012 дата публикации

Vegf antagonist formulations

Номер: US20120178683A1
Автор: Daniel Dix, Kelly Frye, Susan Kautz
Принадлежит: Regeneron Pharmaceuticals Inc

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

Подробнее
Номер записи: 65
12-07-2012 дата публикации

Cofactors for Thrombin Activation of Factor VII and Uses Thereof

Номер: US20120178693A1
Автор: David Kiewlich, David Light, Maxine Bauzon, Terry Hermiston
Принадлежит: Bayer HealthCare LLC

The invention relates to fusion proteins that bind the enzyme thrombin and enhance the activation of the substrate Factor VII to the product Factor VIIa. The invention is also directed to polynucleotides, vectors, host cells, pharmaceutical compositions, and methods of treatment.

Подробнее
Номер записи: 66
19-07-2012 дата публикации

Methods of promoting fat loss comprising administering an alk7 inhibitor

Номер: US20120183540A1
Автор: Jasbir Seehra, John Knopf
Принадлежит: Acceleron Pharma Inc

The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.

Подробнее
Номер записи: 67
19-07-2012 дата публикации

Hiv tat-cd4 hybrid molecules and methods of use thereof

Номер: US20120183557A1
Автор: Indresh K. Srivastava, Jan zur Megede, Rino Rappuoli, Susan Barnett, Victoria A. Sharma
Принадлежит: Novartis Vaccines and Diagnostics Inc

Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.

Подробнее
Номер записи: 68
26-07-2012 дата публикации

Tetranectin-apolipoprotein a-i, lipid particles containing it and its use

Номер: US20120190610A1
Автор: Jean-Luc Mary, Juergen Fingerle, Martin Bader, Monika Baehner, Silke Mohl, Ulrich Kohnert
Принадлежит: Hoffmann La Roche Inc

A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one embodiment the lipid is a second phosphatidylcholine, wherein the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the apolipoprotein is selected from an apolipoprotein that has the amino acid sequence selected from SEQ ID NO: 01, 02, 06, 66, and 67, or is a variant thereof that has at least 70% sequence identity with the selected sequence.

Подробнее
Номер записи: 69
26-07-2012 дата публикации

Recombinant soluble fc receptors

Номер: US20120190821A1
Автор: Peter Sondermann, Robert Huber, Uwe Jacob
Принадлежит: Max Planck Gesellschaft zur Foerderung der Wissenschaften eV

Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycoslyation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host ells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modeling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that an be used to separate and/or enrich antibodies.

Подробнее
Номер записи: 70
26-07-2012 дата публикации

Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses

Номер: US20120190827A1
Автор: Anna-Maria A. HAYS PUTNAM, Denise Krawitz, Feng Tian, Ho Sung Cho, Joseph Sheffer, Richard D. Dimarchi, Stephanie Chu, Thea Norman
Принадлежит: Ambrx Inc

Modified human plasma polypeptides or Fc and uses thereof are provided.

Подробнее
Номер записи: 71
16-08-2012 дата публикации

Compositions and methods for modulating lymphocyte activity

Номер: US20120207759A1
Автор: Jianfei Yang, John R. Sedy, Kenneth M. Murphy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Theresa L. Murphy
Принадлежит: Washington University in St Louis WUSTL

The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.

Подробнее
Номер записи: 72
16-08-2012 дата публикации

Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Номер: US20120207761A1
Автор: Anthony W. Siadak, Joyce M. Lehner, Margaret Dow Moore, Pallavur V. Sivakumar, Stacey R. Dillon, Wayne Kindsvogel, Wenfeng Xu, Yasmin A. Chandrasekher
Принадлежит: Zymogenetics Inc

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.

Подробнее
Номер записи: 73
16-08-2012 дата публикации

Modified agrin-fragment capable of restoring muscle strength for use as a medicament

Номер: US20120208765A1
Автор: Jan Willem Vrijbloed, Stefan Hettwer, Stefan Kucsera
Принадлежит: NEUROTUNE AG

Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use as medicament.

Подробнее
Номер записи: 74
16-08-2012 дата публикации

Human platelet f11 receptor

Номер: US20120208990A1
Автор: Elizabeth Kornecki, Malgorzata B. Sobocka
Принадлежит: Individual

The present invention is directed to isolated nucleic acid molecules encoding human platelet F11 receptors. Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for increasing or decreasing the expression of the human platelet F11 receptor in host cells. The invention further provides a method of screening a substance for the ability of the substance to modify human platelet F11 receptor function, and a method for isolating other human platelet F11 receptor molecules. DNA oligomers capable of hybridizing to the nucleic acid molecule encoding the human platelet F11 receptor are provided, which can be used to detect human platelet F11 receptor in a sample.

Подробнее
Номер записи: 75
23-08-2012 дата публикации

Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2

Номер: US20120214737A1
Автор: Mark Marchionni
Принадлежит: Acorda Therapeutics Inc

The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.

Подробнее
Номер записи: 76
30-08-2012 дата публикации

Freeze-dried fibrin matrices and methods for preparation thereof

Номер: US20120219534A1
Автор: Avner Yayon, Malkit Azachi, Micha Gladnikoff
Принадлежит: Prochon Biotech Ltd

Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.

Подробнее
Номер записи: 77
30-08-2012 дата публикации

Cholinergic/serotoninergic receptor and uses thereof

Номер: US20120219967A1
Автор: Daniel C. Bertrand, David J. Anderson, Earl J. Gubbins, Jinhe Li, John Malysz, Murali Gopalakrishnan, Steven C. Cassar
Принадлежит: AbbVie Inc

The present invention describes new cholinergic/serotoninergic chimeric receptors and provides methods and compositions suitable for screening for ligands such as agonists, antagonists and allosteric modulators of α7 nicotinic acetylcholine receptors.

Подробнее
Номер записи: 78
30-08-2012 дата публикации

Albumin variants

Номер: US20120220530A1
Автор: Andrew Plumridge, Darrell Sleep, Esben Peter Friis, Inger Sandlie, Jan Terje Andersen, Jason Cameron
Принадлежит: Novozymes Biopharma DK AS

The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.

Подробнее
Номер записи: 79
30-08-2012 дата публикации

Composition comprising rna derived from lactic acid bacterium as effective component

Номер: US20120220760A1
Автор: Kazunari Ushida, Ryo Inoue, Takumi Watanabe
Принадлежит: Combi Corp, Kyoto Prefectural Public Univ Corp

A composition has an immunomodulation action, and comprises an RNA derived from a lactic acid bacterium as an effective component. Alternatively, a composition has a cytokine production-modulating action, and includes an RNA derived from a lactic acid bacterium as an effective component.

Подробнее
Номер записи: 80
13-09-2012 дата публикации

Fusion molecules and il-15 variants

Номер: US20120230946A1
Автор: Hing C. Wong, Kai-Ping Han, Peter Rhode, Xiaoyun Zhu
Принадлежит: Altor Bioscience Corp

The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Подробнее
Номер записи: 81
13-09-2012 дата публикации

Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods

Номер: US20120231013A1
Автор: Chadwick T. King, Joshua Silverman, Peng Li, Roy A. Black
Принадлежит: AMGEN INC

The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.

Подробнее
Номер записи: 82
13-09-2012 дата публикации

Lipoprotein complexes and manufacturing and uses thereof

Номер: US20120232005A1
Автор: Daniela Carmen Oniciu, Jean-Louis Dasseux, Rose ACKERMANN
Принадлежит: Cerenis Therapeutics Holding SA

The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.

Подробнее
Номер записи: 83
13-09-2012 дата публикации

METHOD OF IMPROVING TRANSPLANT FUNCTION USING SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1)

Номер: US20120232020A1
Автор: Marc Antonius Seelen
Принадлежит: Celldex Therapeutics Inc

A method is disclosed for inhibiting complement activation in brain-dead organ donors, particularly kidney donors, which leads to improvement of organ function of transplanted organs in recipients. The method involves administration of a complement inhibitory protein, specifically a soluble complement receptor type I (sCR1) polypeptide to the donor prior to harvesting the organ for transplant.

Подробнее
Номер записи: 84
13-09-2012 дата публикации

Method of modulating integrin mediated cellular activity and agents useful for same

Номер: US20120232249A1
Автор: Michael Valentine Agrez, Nuzhat Ahmed
Принадлежит: Individual

There is disclosed agents capable of inhibiting the binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, and methods of modulating the activity of a cell utilising the agents. The methods are particularly suitable for inhibiting the growth of cancer cells.

Подробнее
Номер записи: 85
27-09-2012 дата публикации

Microorganisms for imaging and/or treatment of tumors

Номер: US20120244068A1
Автор: Aladar A. Szalay, Nanhai Chen, Qian Zhang, Yong A. Yu, Yuman Fong
Принадлежит: Individual

Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents.

Подробнее
Номер записи: 86
27-09-2012 дата публикации

Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor

Номер: US20120244153A1
Автор: Jeffrey L. Browning, Jenny P-Y Ting
Принадлежит: BIOGEN IDEC MA INC, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

The invention relates to the treatment of demyelinating disorders, e.g. multiple sclerosis, using a soluble lymphotoxin beta receptor (LTβR) as an inhibitor of the lymphotoxin pathway.

Подробнее
Номер записи: 87
27-09-2012 дата публикации

High pressure refolding of monoclonal antibody aggregates

Номер: US20120245329A1
Автор: Lyndal K. Hesterberg, Matthew B. Seefeldt, Robert Nelson, Theodore W. Randolph
Принадлежит: Barfold Inc

Methods for refolding antibodies, particularly monoclonal antibodies, from aggregated and/or denatured preparations by subjecting the antibody preparation to high hydrostatic pressure are provided. Refolded preparations of antibodies produced by the methods described herein are also provided.

Подробнее
Номер записи: 88
04-10-2012 дата публикации

Methods and Compositions for the Treatment of Immune Disorders

Номер: US20120251539A1
Автор: Haitao Wen, Jenny P.-Y. Ting
Принадлежит: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

The present invention provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, which results in reducing the plexin-A4 activity in the subject, and thereby treating the immune-related disorder Inhibitors of plexin-A4 activity include, for example, plexin-A4 antibodies and plexin-A4 fusion proteins. The present invention further provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin-3A (Sema3A) activity, which results in reducing the Sema3A activity in the subject, thereby treating the immune-related disorder. Inhibitors of Sema3A activity include, for example, Sema3A antibodies and Sema3A fusion proteins.

Подробнее
Номер записи: 89
04-10-2012 дата публикации

Optimized messenger rna

Номер: US20120252117A1
Автор: Allan M. Miller, Douglas A. Treco, Richard F Selden
Принадлежит: Individual

The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.

Подробнее
Номер записи: 90
04-10-2012 дата публикации

Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same

Номер: US20120253008A1
Автор: Carlo Boutton, Hilde Adi Pierrette Revets, Peter Verheesen, Stephanie Staelens
Принадлежит: Ablynx NV

The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs.

Подробнее
Номер записи: 91
11-10-2012 дата публикации

Methods of using btl-ii proteins

Номер: US20120258097A1
Автор: Joanne L. Viney, Peter R. Baum, Sabine S. Escobar
Принадлежит: Immunex Corp

The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.

Подробнее
Номер записи: 92
18-10-2012 дата публикации

Mhc peptide complexes and uses thereof in infectious diseases

Номер: US20120264161A1
Автор: Henrik Pedersen, Jørgen Schøller, Liselotte Brix
Принадлежит: Dako Denmark ApS

Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.

Подробнее
Номер записи: 93
18-10-2012 дата публикации

Reversible platelet inhibition

Номер: US20120264815A1
Автор: Bruce A. Sullenger, Nanette Que-Gewirth, Sabah Oney, Shahid Nimjee
Принадлежит: Duke University

The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.

Подробнее
Номер записи: 94
25-10-2012 дата публикации

SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)

Номер: US20120269837A1
Автор: Chiara Cabrele, Kerstin Wendt, Luis Moroder, Peter Sondermann, Robert Huber, Uwe Jacob
Принадлежит: Max Planck Gesellschaft zur Foerderung der Wissenschaften eV

This invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either FcγRIIb and FcγRIIa.

Подробнее
Номер записи: 95
25-10-2012 дата публикации

Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices

Номер: US20120270810A1
Автор: Guy Tomer, Orahn Preiss-Bloom
Принадлежит: Lifebond Ltd

Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the enzyme molecules are modified to alter the perceived volume of the enzyme molecules in the crosslinked matrix being formed. Methods of production and of use are also provided.

Подробнее
Номер записи: 96
01-11-2012 дата публикации

Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same

Номер: US20120276142A1
Автор: Andrew Y. Choo, David B. Weiner, Jean D. Boyer, Joo-Sung Yang, Michele Kutzler
Принадлежит: Individual

Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors are disclosed as well as recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. The immunomodulatory effect following delivery of IL-15 and CD40L, with or without immunogens, is disclosed as are various nucleic acid molecules and compositions thereof used for delivering such proteins and methods of using such compositions.

Подробнее
Номер записи: 97
22-11-2012 дата публикации

Modulation of glucagon receptor expression

Номер: US20120295958A1
Автор: Susan M. Freier
Принадлежит: ISIS PHARMACEUTICALS INC

Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.

Подробнее
Номер записи: 98
29-11-2012 дата публикации

Antibody Mimetic Scaffolds

Номер: US20120302492A1
Автор: Fang Jin, Marian Seto, Richard Harkins, Ye Jin
Принадлежит: Bayer HealthCare LLC

Provided herein are protein scaffolds, e.g. antibody mimetic scaffolds, comprising a three finger protein domain that specifically bind to target molecules, polynucleotides encoding such proteins, methods of using such proteins, and libraries of such scaffolds.

Подробнее
Номер записи: 99
29-11-2012 дата публикации

Isolated laminin-421

Номер: US20120302512A1
Автор: Karl Tryggvason, Sergey Rodin
Принадлежит: BIOLAMINA AB

The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin β2 chain, expression vectors and host cells thereof.

Подробнее
Номер записи: 100